Non-Hormonal Menopause Treatments 2026: Complete Tracking Guide

The landscape of non-hormonal menopause treatments has expanded significantly. In 2026, women have more options than ever for managing hot flashes without hormone therapy. This guide covers what's available and how to track your response.

Non-hormonal treatment categories

NK receptor antagonists (newest class)

Veoza (fezolinetant):

• FDA approved 2023
• NK3 receptor antagonist
• Targets hot flashes specifically
• Once-daily tablet
• Requires liver monitoring

Lynkuet (elinzanetant):

• Dual NK1/NK3 antagonist
• Targets both hot flashes and sleep
• Once-daily tablet
• Additional sleep quality benefits

SSRIs/SNRIs (off-label use)

Paroxetine (Brisdelle):

• Only SSRI FDA-approved for hot flashes
• Low strength (7.5mg)
• Works on serotonin pathways

Venlafaxine and others:

• Sometimes prescribed off-label
• May help some women
• Different mechanism than NK antagonists

Other options

Gabapentin:

• Originally for seizures/nerve pain
• Used off-label for hot flashes
• May help with sleep
• Used multiple times daily

Clonidine:

• Blood pressure medication
• Modest hot flash reduction
• Patch or oral forms

What to track for any non-hormonal treatment

Core metrics (all treatments)

Hot flash tracking:

• Daily frequency count
• Severity rating (1-5 consistent scale)
• Duration of episodes
• Time of day distribution
• Night sweats separately

Impact assessment:

• Sleep quality (1-10)
• Daily function limitations
• Work impact
• Social activity impact

Treatment-specific tracking

For NK antagonists (Veoza, Lynkuet):

• Liver monitoring test dates/results
• Gastrointestinal symptoms
• Sleep improvements (especially Lynkuet)

For SSRIs/SNRIs:

• Mood changes
• Sexual function
• Adjustment period symptoms
• Taper concerns

For gabapentin:

• Drowsiness or dizziness
• Timing of applications
• Strength adjustments

Choosing between options: what your data shows

Track baseline symptoms before any treatment:

If hot flashes are primary concern:

All non-hormonal options target hot flashes. NK antagonists are specifically designed for this.

If sleep is equally important:

Lynkuet's dual mechanism may particularly help. Gabapentin also has sedating properties.

If you have other considerations:

• Depression/anxiety history → SSRI might serve dual purpose
• Blood pressure concerns → Clonidine might address both
• Medication interactions → Discuss full list with provider

Tracking framework: finding what works

Phase 1: Baseline (1-2 weeks before treatment)

Document your starting point:

• Average daily hot flashes: ___
• Average severity: ___
• Sleep quality baseline: ___
• Quality of life rating: ___

Phase 2: Early treatment (weeks 1-4)

Track response:

• Weekly hot flash averages
• Side effect log
• Sleep changes
• Any concerns

Phase 3: Assessment (weeks 8-12)

Evaluate:

• Percent reduction from baseline
• Side effect trajectory (improving?)
• Overall satisfaction
• Need for adjustment?

Comparing your options

Quick comparison table

| Treatment | Primary Target | Dosing | Key Monitoring | |-----------|----------------|--------|----------------| | Veoza | Hot flashes | Once daily | Liver function | | Lynkuet | Hot flashes + sleep | Once daily | Per guidance | | Paroxetine | Hot flashes | Once daily | Mood, adjustment | | Gabapentin | Hot flashes, sleep | Multiple daily | Sedation | | Clonidine | Hot flashes | Varies | Blood pressure |

Questions for your healthcare provider

Based on your tracking, discuss:

1. Given my hot flash frequency and severity, which options fit?
2. Are there contraindications based on my medical history?
3. How do side effect profiles compare for my situation?
4. What's the expected timeline for improvement?
5. What monitoring is required?

If one treatment doesn't work

Your tracking data helps inform next steps:

• Inadequate response: Data showing persistent symptoms supports trying alternative
• Side effect concerns: Documented issues help provider adjust
• Partial response: May indicate strength adjustment or combination approaches

Frequently asked questions

Can I use non-hormonal treatments with HRT?

Some combinations may be appropriate. Your healthcare provider can assess based on your specific situation and goals.

Which non-hormonal treatment is most effective?

Individual response varies. Clinical trials show NK antagonists reduce hot flashes by approximately 60% on average. Your tracking reveals your personal response.

Are non-hormonal treatments as effective as HRT?

HRT addresses multiple menopause symptoms by replacing hormones. Non-hormonal options target specific symptoms (primarily hot flashes). Effectiveness depends on your symptom profile and what you're treating.

How long should I try a treatment before switching?

Most guidelines suggest 8-12 weeks for adequate trial. Your tracking data helps assess whether response is building or plateaued.

What this page is / is not

This page provides an overview of non-hormonal treatment options and tracking guidance. It does not recommend specific treatments or provide medical advice. Discuss options with your healthcare provider.